NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

September 26, 2019

Study Completion Date

October 21, 2019

Conditions

Amyloidosis

Interventions

DRUG

Carfilzomib

Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.

DRUG

Thalidomide

50mg capsule.

DRUG

Dexamethasone

2mg tablet.

Trial Locations (14)

PL6 8DH

Derriford Hospital, Plymouth

BH7 7DW

Royal Bournemouth General Hospital, Bournemouth

SE1 7EH

Guy's Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

SO16 6YD

Southampton General Hospital, Southampton

LE1 5WW

Leicester Royal Infirmary, Leicester

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

S10 2JF

Royal Hallamshire Hospital, Sheffield

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

B15 2TH

Birmingham Queen Elizabeth Hospital, Birmingham

B9 5SS

Birmingham Heartlands Hospital, Birmingham

LS9 7TF

St James' University Hospital, Leeds

BS2 8ED

Bristol Haematology and Oncology Centre, Bristol

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

All Listed Sponsors

lead

University College, London

OTHER